Developer docs
API playgroundTry for free, no card

Search company profiles

Artificial

Full company profile

uuid0000fhq

Namestring
Artificial
Websiteurl
artificial.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Artificial is a Palo Alto-based private software company founded in 2018 that builds an AI-integrated lab automation platform for enterprise customers in life sciences and diagnostics. The platform is positioned as an embedded operating layer across three lab workflow domains: imaging systems, automation platforms, and informatics — intended to enable high-throughput testing, automate repetitive laboratory tasks, and improve diagnostic accuracy. The company targets three primary customer segments: pharmaceutical R&D laboratories (primary), diagnostic laboratories, and academic/private research institutions, addressing pain points such as pharmaceutical R&D pressure, diagnostic workforce shortages, and laboratory modernization initiatives.

The core technology is described as an AI-integrated lab automation platform whose differentiator is integration and interoperability across existing lab infrastructure, with AI embedded into imaging, automation, and informatics rather than offered as a standalone analytics product. Specific underlying models, data assets, patents, and technical architecture details are not disclosed in the available sources, limiting technical due diligence. The company sells through an enterprise B2B field sales motion, with revenue generated via enterprise software licensing and subscription. Pricing is not publicly disclosed and is presumed to be quote-based, consistent with enterprise SaaS norms.

The company is venture-backed, having closed a $21.5 million Series A in May 2021 led by M12 (Microsoft's venture fund) with participation from Playground Global and AME Cloud Ventures. Leadership includes CEO and co-founder David Fuller, co-founder and Chief Product Officer Nikhita Singh, and VP of Engineering James Branigan. Headcount sits in the 11-50 range. The company currently serves North America (USA), with stated intent to grow global operations. A notable data point: the artificial.com domain is currently listed for sale by a third-party domain marketplace (Snagged) at a $250,000 minimum offer, which is ambiguous — it may reflect lapsed domain ownership, a separate brand domain, or unrelated third-party listing — and warrants verification before any investment decision.

Short descriptiontext

Artificial is a Palo Alto-based enterprise software company, founded in 2018, that builds an AI-integrated lab automation platform for pharmaceutical R&D, diagnostic, and research laboratories. It sells via enterprise subscriptions targeting imaging, automation, and informatics workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lab automation software, AI laboratory platform, laboratory informatics, pharmaceutical R&D automation, diagnostic workflow automation
Industry2 codes
PRIMARYHLAGAJAG
Lab Automation, Instrument Control & Workflow Orchestration Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAEANAJ
AI Application Enablement Platforms (Copilot/Agent Frameworks, SDKs)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Computer Integrated Systems Design7373
Product category
Laboratory Automation Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Enterprise Software Licenses/Subscriptions
TypeSubscription Recurring
Description

Artificial generates revenue through enterprise software licensing and subscriptions for its lab automation platform, as evidenced by its venture funding and focus on product development acceleration and global operations expansion.

finsmes.com
Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Artificial develops an AI-integrated lab automation platform that delivers intelligent imaging, automation, and informatics capabilities for modern research and diagnostics laboratories. The platform enables high-throughput testing, automates repetitive laboratory tasks, and improves diagnostics accuracy for pharmaceutical R&D, clinical diagnostic, and research institution customers. It functions as an embedded operating layer within laboratory infrastructure rather than a standalone analytics tool.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • AI in Lab Automation market projected to grow from USD 456.5 million (2026) to USD 1.39 billion by 2036 at 11.8% CAGR
Product overview1 text field

No product information available in the provided sources. The sources do not contain details from the actual company website or product pages of Artificial (the Palo Alto-based lab automation software company). One source references artificial.com as a domain name being offered for sale, which is unrelated to the company's actual web presence.

Product and service1 record
1Lab Automation Platform
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sartorius provides bioprocess and lab analytics software alongside its instruments, serving similar biopharma customers with embedded data and automation capabilities — a broad incumbent adjacent to Artificial's lab automation thesis.

TypeBroad incumbent
Description

Thermo Fisher's SampleManager LIMS and broader digital lab offerings target the same pharma and diagnostic lab buyers, but as part of a much larger life sciences tools portfolio — a broad incumbent rather than a focused automation platform.

TypeBroad incumbent
Description

Agilent's CrossLab and OpenLab lab informatics and automation software serve pharmaceutical and diagnostic labs, overlapping with Artificial's offering as part of a broad analytical instruments and software portfolio.

TypeEmerging player
Description

Scitara provides a lab integration platform (Scientific Integration Platform) connecting instruments, LIMS, and informatics — an emerging competitor specifically focused on the lab interoperability wedge Artificial claims.

TypeDirect peer
Description

Benchling is a cloud-based life sciences R&D platform covering lab notebooks, inventory, and workflow automation for pharma and biotech — directly comparable to Artificial's lab automation platform targeting the same buyer profile.

TypeDirect peer
Description

LabVantage provides an enterprise LIMS and lab informatics platform used by pharmaceutical, diagnostic, and research laboratories, competing for the same lab modernization budgets Artificial targets.

TypeDirect peer
Description

LabWare is an established LIMS and laboratory automation software vendor serving regulated labs in pharma, diagnostics, and research — a like-for-like competitor for the lab automation platform category.

TypeDirect peer
Description

Dotmatics offers a scientific R&D informatics platform spanning ELN, data management, and lab workflow automation for life sciences — overlapping Artificial's pharma R&D and research institution use cases.

TypeEmerging player
Description

TetraScience is a life sciences R&D data cloud that integrates lab instrument data into analytics-ready pipelines — a narrower but overlapping play on the lab data interoperability layer Artificial emphasizes.

TypeDirect peer
Description

Genedata delivers enterprise scientific informatics and workflow automation for biopharma R&D, including experiment automation and data integration — directly comparable to Artificial's embedded automation thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Artificial

Laboratory Automation Softwareartificial.com

Artificial is a Palo Alto-based enterprise software company, founded in 2018, that builds an AI-integrated lab automation platform for pharmaceutical R&D, diagnostic, and research laboratories. It sells via enterprise subscriptions targeting imaging, automation, and informatics workflows.

What Artificial does

Artificial is a Palo Alto-based private software company founded in 2018 that builds an AI-integrated lab automation platform for enterprise customers in life sciences and diagnostics. The platform is positioned as an embedded operating layer across three lab workflow domains: imaging systems, automation platforms, and informatics — intended to enable high-throughput testing, automate repetitive laboratory tasks, and improve diagnostic accuracy. The company targets three primary customer segments: pharmaceutical R&D laboratories (primary), diagnostic laboratories, and academic/private research institutions, addressing pain points such as pharmaceutical R&D pressure, diagnostic workforce shortages, and laboratory modernization initiatives.

The core technology is described as an AI-integrated lab automation platform whose differentiator is integration and interoperability across existing lab infrastructure, with AI embedded into imaging, automation, and informatics rather than offered as a standalone analytics product. Specific underlying models, data assets, patents, and technical architecture details are not disclosed in the available sources, limiting technical due diligence. The company sells through an enterprise B2B field sales motion, with revenue generated via enterprise software licensing and subscription. Pricing is not publicly disclosed and is presumed to be quote-based, consistent with enterprise SaaS norms.

The company is venture-backed, having closed a $21.5 million Series A in May 2021 led by M12 (Microsoft's venture fund) with participation from Playground Global and AME Cloud Ventures. Leadership includes CEO and co-founder David Fuller, co-founder and Chief Product Officer Nikhita Singh, and VP of Engineering James Branigan. Headcount sits in the 11-50 range. The company currently serves North America (USA), with stated intent to grow global operations. A notable data point: the artificial.com domain is currently listed for sale by a third-party domain marketplace (Snagged) at a $250,000 minimum offer, which is ambiguous — it may reflect lapsed domain ownership, a separate brand domain, or unrelated third-party listing — and warrants verification before any investment decision.

Artificial firmographics

Firmographics
Name
Artificial
Website
https://artificial.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Artificial is a Palo Alto-based enterprise software company, founded in 2018, that builds an AI-integrated lab automation platform for pharmaceutical R&D, diagnostic, and research laboratories. It sells via enterprise subscriptions targeting imaging, automation, and informatics workflows.
Ownership category
akta.pro rank

Artificial industry classification

Industry
Product category
Laboratory Automation Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAG
Lab Automation, Instrument Control & Workflow Orchestration Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAEANAJ
AI Application Enablement Platforms (Copilot/Agent Frameworks, SDKs)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise

Keywords

  • Lab automation software
  • AI laboratory platform
  • Laboratory informatics
  • Pharmaceutical R&D automation
  • Diagnostic workflow automation

Where Artificial is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Artificial business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Enterprise Software Licenses/Subscriptions: Artificial generates revenue through enterprise software licensing and subscriptions for its lab automation platform, as evidenced by its venture funding and focus on product development acceleration and global operations expansion.

Go-to-market motion1 record

Artificial product offering

Product offering

Core offering

Artificial develops an AI-integrated lab automation platform that delivers intelligent imaging, automation, and informatics capabilities for modern research and diagnostics laboratories. The platform enables high-throughput testing, automates repetitive laboratory tasks, and improves diagnostics accuracy for pharmaceutical R&D, clinical diagnostic, and research institution customers. It functions as an embedded operating layer within laboratory infrastructure rather than a standalone analytics tool.

Product overview

No product information available in the provided sources. The sources do not contain details from the actual company website or product pages of Artificial (the Palo Alto-based lab automation software company). One source references artificial.com as a domain name being offered for sale, which is unrelated to the company's actual web presence.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lab Automation Platform

Quantifiable outcome

  • AI in Lab Automation market projected to grow from USD 456.5 million (2026) to USD 1.39 billion by 2036 at 11.8% CAGR

Companies that use Artificial

Customer profile

Segments3 records

Ideal customer profiles3 records

Artificial technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Artificial partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves3 records

Expansion highlights4 records

Artificial competitors and assessment

Company assessment

Broad incumbents

  • Sartorius: Sartorius provides bioprocess and lab analytics software alongside its instruments, serving similar biopharma customers with embedded data and automation capabilities — a broad incumbent adjacent to Artificial's lab automation thesis.
  • Thermo Fisher Scientific (SampleManager LIMS): Thermo Fisher's SampleManager LIMS and broader digital lab offerings target the same pharma and diagnostic lab buyers, but as part of a much larger life sciences tools portfolio — a broad incumbent rather than a focused automation platform.
  • Agilent Technologies (CrossLab / lab software): Agilent's CrossLab and OpenLab lab informatics and automation software serve pharmaceutical and diagnostic labs, overlapping with Artificial's offering as part of a broad analytical instruments and software portfolio.

Emerging players

  • Scitara: Scitara provides a lab integration platform (Scientific Integration Platform) connecting instruments, LIMS, and informatics — an emerging competitor specifically focused on the lab interoperability wedge Artificial claims.
  • TetraScience: TetraScience is a life sciences R&D data cloud that integrates lab instrument data into analytics-ready pipelines — a narrower but overlapping play on the lab data interoperability layer Artificial emphasizes.

Direct peers

  • Benchling: Benchling is a cloud-based life sciences R&D platform covering lab notebooks, inventory, and workflow automation for pharma and biotech — directly comparable to Artificial's lab automation platform targeting the same buyer profile.
  • LabVantage Solutions: LabVantage provides an enterprise LIMS and lab informatics platform used by pharmaceutical, diagnostic, and research laboratories, competing for the same lab modernization budgets Artificial targets.
  • LabWare: LabWare is an established LIMS and laboratory automation software vendor serving regulated labs in pharma, diagnostics, and research — a like-for-like competitor for the lab automation platform category.
  • Dotmatics: Dotmatics offers a scientific R&D informatics platform spanning ELN, data management, and lab workflow automation for life sciences — overlapping Artificial's pharma R&D and research institution use cases.
  • Genedata: Genedata delivers enterprise scientific informatics and workflow automation for biopharma R&D, including experiment automation and data integration — directly comparable to Artificial's embedded automation thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Artificial social profiles

Digital presence

Artificial financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Artificial leadership team

Management profile

Number of profiles

Profiles3 records

Artificial funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Artificial M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artificial

What does Artificial do?

Artificial develops an AI-integrated lab automation platform that delivers intelligent imaging, automation, and informatics capabilities for modern research and diagnostics laboratories. The platform enables high-throughput testing, automates repetitive laboratory tasks, and improves diagnostics accuracy for pharmaceutical R&D, clinical diagnostic, and research institution customers. It functions as an embedded operating layer within laboratory infrastructure rather than a standalone analytics tool.

Is Artificial a public or private company?

Artificial is a private company. It is classified as venture growth investor backed and is currently operating.

When was Artificial founded?

Artificial was founded in 2017. It employs 11 to 50 people.

Where is Artificial based?

Artificial is headquartered in Palo Alto, United States, in the North America region.

How does Artificial make money?

One revenue line is on record: enterprise Software Licenses/Subscriptions.

Who are Artificial's main competitors?

Broad incumbents on record are Sartorius, Thermo Fisher Scientific (SampleManager LIMS) and Agilent Technologies (CrossLab / lab software). Emerging players are Scitara and TetraScience. Direct peers are Benchling, LabVantage Solutions, LabWare, Dotmatics and Genedata.

Does Artificial have an API?

No public API is recorded for Artificial.

What industry is Artificial in?

Artificial's product category is Laboratory Automation Software. Its primary akta.pro industry code is HLAGAJAG, Lab Automation, Instrument Control & Workflow Orchestration Software, with a secondary code of HDAEANAJ, AI Application Enablement Platforms (Copilot/Agent Frameworks, SDKs). Its NAICS code is 54151 and its SIC code is 7373.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The New York TimesIndependent Studio Buys Movie About OpenAI That Amazon DroppedNeon purchased the film 'Artificial' about Sam Altman and OpenAI after Amazon dropped it. The film, featuring Andrew Garfield as Altman and Ike Barinholtz as Musk, will release later this year. The deal price was not disclosed.EntarabiOmantel Innovation Labs selects 8 startups for Omantel AcceleratorOmantel Innovation Labs selected eight startups for its seventh accelerator cohort, focusing on AI, cybersecurity, and fintech. The startups include Algo AI, Artificial Horizon, and Eisala, among others. They will receive mentorship and access to Omantel's innovation ecosystem.Morningstar'Susty Code' Protocol Launched for Maximizing Truth & Morality in AIArtificial Epistemics announced the launch of the Sustainability Code (Susty Code), an epistemic rule-based protocol designed to quality-control truth and morality in AI knowledge processing before dissemination. The protocol uses principles from science, logic, value theory, and epistemology to evaluate fact and value claims, marking what the company claims is the first attempt to address AI misinformation at the pre-action level of knowledge processing. The company intends to license the protocol and work with leading AI producers to integrate it into current and future AI systems.Business Insider23 of the most promising healthcare startups of 2021, according to top VCsTwenty-three healthcare startups were highlighted as promising in 2021 by top VCs, including Artificial, Asher Bio, and K Health. Funding amounts range from $2.55 million to $273.3 million, with companies covering areas like lab automation, cancer treatment, and telehealth. The list reflects trends such as virtual care and in-home services.FinSMEsArtificial Raises $21.5M in Series A FundingArtificial, a software company based in Palo Alto, CA, has closed a $21.5 million Series A funding round led by M12 with participation from Playground Global and AME Cloud Ventures. The company plans to utilize the capital to accelerate product development, expand its team, and grow its global life science partnerships.